Document is current
Any future updates will be listed below
-
Authors
Hillege, Lars E. https://orcid.org/0000-0001-7010-7610
Stevens, Milou A. M. https://orcid.org/0009-0009-2152-6734
Kristen, Paulien A. J. https://orcid.org/0000-0002-2778-3039
de Vos-Geelen, Judith https://orcid.org/0000-0003-2578-1766
Penders, John https://orcid.org/0000-0001-9146-5919
Redinbo, Matthew R. https://orcid.org/0000-0003-0814-5346
Smidt, Marjolein L. https://orcid.org/0000-0002-8328-1869
- License Information
-
More Information
Article History
Received: 10 September 2024
Accepted: 5 November 2024
First Online: 13 November 2024
Declarations
:
: JVG has served as a consultant for Amgen, AstraZeneca, MSD, Pierre Fabre, and Servier, and has received institutional research funding from Servier, all outside the submitted work. MRR has received funding grants from Merck & Co. Inc. and Eli Lilly and Company, and is a board member of Symberix, Inc., all outside the submitted work. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
